Skip to main content

Technology Transfer: NIH-Private Sector Partnership in the Development of Taxol

GAO-03-829 Published: Jun 04, 2003. Publicly Released: Jun 06, 2003.
Jump To:
Skip to Highlights

Highlights

The transfer of technology from government-funded medical research laboratories to the private sector aims to have new pharmaceuticals brought to market more efficiently than would be possible for a federal agency acting alone. Much of the pharmaceutical-related technology transfer originates with research funded by the National Institutes of Health (NIH). GAO was asked to examine the legal and financial issues involved in technology transfers as illustrated by the research, development, and commercialization of Taxol. Taxol was developed through a cooperative research and development agreement (CRADA) between NIH and the Bristol-Meyers Squibb Company (BMS) and by 2001 had become the best-selling cancer drug in history. Specifically, GAO examined (1) how the technology transfer partnership affected the research and development of Taxol, (2) what NIH's financial investment was in Taxol-related research, and what the financial outcomes were of the technology transfer process related to Taxol, and (3) what factors influenced how NIH exercised its authority in Taxol-related technology transfer activities. GAO reviewed relevant materials and statutes governing technology transfer, reviewed the patent history of Taxol, interviewed NIH and BMS officials, and reviewed data on NIH's financial investment and drug pricing policies.

Full Report

Office of Public Affairs

Topics

Cooperative agreementsLaboratoriesMedical researchPharmaceutical industryPharmacological researchTechnology transferPrivate sectorRoyalty paymentsDrugsCancer